Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review

Paul L Feingold; Mei Li M Kwong; Jeremy L Davis; Udo Rudloff

doi:10.1002/jso.24476

Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review

J Surg Oncol. 2017 Feb;115(2):192-201. doi: 10.1002/jso.24476. Epub 2016 Nov 23.

Authors

Paul L Feingold¹, Mei Li M Kwong¹, Jeremy L Davis¹, Udo Rudloff¹

Affiliation

¹ Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

PMID: 27878811
DOI: 10.1002/jso.24476

Abstract

The peritoneal surface is a frequent site of recurrence following surgery for gastric cancer. A systematic review and random effect analysis was undertaken to analyze current literature regarding the role of adjuvant intraperitoneal chemotherapy in gastric cancer. While pooled analysis supports the use of adjuvant IP chemotherapy in resectable gastric cancer, maximal benefit occured with intra-operative delivery, and possibly the use of MMC. J. Surg. Oncol. 2017;115:192-201. © 2016 Wiley Periodicals, Inc.

Keywords: adjuvant regional chemotherapy; gastrointestinal malignancies; heated intraperitoneal chemotherapy (HIPEC); peritoneal carcinomatosis; systematic review.

Publication types

Review
Systematic Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chemotherapy, Adjuvant
Chemotherapy, Cancer, Regional Perfusion
Humans
Injections, Intraperitoneal
Peritoneal Neoplasms / drug therapy*
Peritoneal Neoplasms / secondary
Prognosis
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology